New info = lower risk = ONCY still undervalued
You remove the check point inhibitor nonsense. What is left?
A PIII ready company with a clear registration path.
Easy target endpoints and statistically results that will certainly be replicated.
Partial funded by Aldai Nortye deal -
So, this is pretty sweet and dirt cheap as an investment.
The acquirer is probably a wealth fund and also the same big Pharma.
Valuation is a bit lower but still in the multi-billions. So who cares.
Management should self inspect. Drop rate need to be address- give people tylenol!!!!
No more BS sciences. Admit that virus mechanism of action is complicated and adding another factor to it such as a check point inbitor is stupid. Stop the commercial promo non sense.